India's BDR partners for push in Latin America
This article was originally published in Scrip
Executive Summary
BDR Pharmaceuticals, which previously caused a stir with its application for a compulsory license for Bristol-Myers Squibb's anticancer Sprycel (dasatinib) in India, appears to be readying for a significant scale-up in the $60bn Latin American market.